Regeneron Pharmaceuticals: Eczema trials

The registry lists 21 Eczema studies with Regeneron Pharmaceuticals as lead sponsor. 1 are open to participants now and 12 have results posted.

Phase 1 4Phase 2 9Phase 3 5Phase 4 1No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic DermatitisRecruitingNCT07527923Phase 1
• Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic DermatitisTerminatedNCT03738423Phase 2Results posted
• Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic DermatitisTerminatedNCT03736967Phase 2Results posted
• Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic DermatitisCompletedNCT03054428Phase 3Results posted
• A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically AdvisableCompletedNCT02755649Phase 3Results posted
• A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema)CompletedNCT02407756Phase 2Results posted
• A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD)CompletedNCT02395133Phase 3Results posted
• Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic DermatitisCompletedNCT02260986Phase 3Results posted
• Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)CompletedNCT02210780Phase 2Results posted
• Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)CompletedNCT01979016Phase 2Results posted
• Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic DermatitisCompletedNCT01859988Phase 2Results posted
• Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD)CompletedNCT01639040Phase 2Results posted
• Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic DermatitisCompletedNCT01548404Phase 2Results posted
• Study of Growth and Bone Mineral Density in Children With Atopic Dermatitis (AD) Treated With DupilumabWithdrawnNCT07187089Phase 4
• Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic DermatitisCompletedNCT05203380
• Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic DermatitisCompletedNCT04287608
• Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)Active, not recruitingNCT03428646
• Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)CompletedNCT02647086Phase 1
• Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)Active, not recruitingNCT02612454Phase 3
• Study to Assess the Clinical Activity of a Sequential Dose of REGN846 on Refractory Pruritus in Patients With Atopic DermatitisTerminatedNCT01605708Phase 1/2
• Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic DermatitisCompletedNCT01385657Phase 1